Clinical Trials Browser

Phase 1/2 × Sarcoma × pazopanib × Clear all

NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT05180695 2026-02-10

AMPHISARC

Phase 1/2 Active not recruiting

Sarcoma

NCT03660930 2025-04-30

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Phase 1/2 Terminated

19 enrolled 26 charts

Sarcoma

NCT01975519 2020-05-20

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Phase 1/2 Completed

111 enrolled 15 charts

Hemangiosarcoma, Sarcoma

NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Phase 1/2 Terminated

5 enrolled 6 charts

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

NCT01719302 2016-06-16

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Phase 1/2 Completed

Sarcoma